Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line

Leonetti, Carlo; Biroccio, Annamaria; Benassi, Barbara; Stringaro, Annarita; Stoppacciaro, Antonella; Semple, Sean C.; Zupi, Gabriella

doi:10.1038/sj.cgt.7700326

Cited by 61 publications

(38 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Our group reported that the encapsulation of c-myc antisense oligonucleotides in liposomes significantly increased the therapeutic efficacy of oligos compared to free administration. 26 This effect was consistent with an increased tumor accumulation and homogeneous distribution of c-myc antisense within the tumor due to an improvement pharmacokinetic behavior and plasma AUC of the oligos. Moreover, the preferential accumulation of liposomes in the sites of inflammation and in the tumors can also account for the increased amount of oligos in the tumor.…”

Section: Discussionsupporting

confidence: 68%

In vivo administration of liposomal vincristine sensitizes drug‐resistant human solid tumors

Leonetti

Scarsella²,

Semple

et al. 2004

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 68%

In vivo administration of liposomal vincristine sensitizes drug‐resistant human solid tumors

Leonetti

Scarsella²,

Semple

et al. 2004

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

“…Further enhancement in delivery of genetic medicine invivo may be attained with other vesicles such as immunoliposomes (Watanabe et al 2000), thermosensitive liposomes (Gaber et al 1996;Needham et al 2000), coated lipoplexes (Stuart et al 2000) or stabilized antisense lipid particles (SALPs) (Leonetti et al 2001;Mui et al 2001). Immunoliposomes and thermosensitive liposomes, although showing some promise in cell culture, have not readily been adapted for in-vivo usage.…”

Section: The Future For Cationic Liposomes and Lipoplexes In Nucleic mentioning

confidence: 99%

Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo

Dass

2002

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Cationic liposomes bind with nucleic acids such as plasmids and oligodeoxynucleotides to form complexes known as lipoplexes. Although these lipoplexes have several advantages over other forms of nucleic acid transfer methods in cell culture and in-vivo, toxicity remains a problem, especially in-vivo. Nevertheless, these carriers have been used in clinical trials against cystic brosis and cancer and their usage is attributed mainly to their versatility, especially when it comes to the range of routes available for administration of nucleic-acid-based drugs in-vivo.

show abstract

“…Liposomal encapsulation of AON may provide more sustained levels of oligonucleotides, with higher concentrations delivered to cells, and allow delivery of AON without requiring phosphothioate modification of all residues. Several lipid formulations have been used for intracellular delivery of nuclease-resistant oligonucleotides (Tari et al, 1998;Garcia-Chaumont et al, 2000;Pagnan et al, 2000;Leonetti et al, 2001). We have designed novel cationic liposomes for in vivo delivery of nuclease-sensitive or phosphorothioated oligonucleotides (Gokhale et al, 1997(Gokhale et al, , 1999.…”

Section: Evolution Of the Antisense Raf-1 Therapeutic Strategymentioning

confidence: 99%

RAF antisense oligonucleotide as a tumor radiosensitizer

Kasid

Dritschilo

2003

Oncogene

View full text Add to dashboard Cite

The RAF-1 serine-threonine kinase plays a central role in signal transduction pathways involved in cell survival and proliferation. The concept of RAF-1-targeted disruption of cell signaling for therapeutic purposes was first advanced in 1989 with the demonstration of tumor growth inhibition in athymic mice and radiosensitization of human squamous carcinoma cells transfected with a vector expressing antisense cDNA. However, the clinical application of antisense strategies has awaited the development of improved antisense oligonucleotide technologies and drug delivery methods. Nuclease-resistant phosphorothioated antisense oligonucleotides have been the focus of pharmaceutical industry attention. In vivo delivery of nuclease-sensitive, natural backbone/phosphodiester oligonucleotides has remained a formidable challenge. Liposomal encapsulation of antisense oligonucleotides protects them from degradation and enhances drug delivery. Here, we review the importance of targeting RAF-1 signaling in cancer therapy and the preclinical and clinical experiences with a liposomal formulation of a nuclease-sensitive, ends-modified antisense RAF oligonucleotide.

show abstract

Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line

Cited by 61 publications

References 26 publications

In vivo administration of liposomal vincristine sensitizes drug‐resistant human solid tumors

In vivo administration of liposomal vincristine sensitizes drug‐resistant human solid tumors

Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo

RAF antisense oligonucleotide as a tumor radiosensitizer

Contact Info

Product

Resources

About